Literature DB >> 8260611

Striatal D2/acetylcholine interactions: PET studies of the vesamicol receptor.

M Ingvar1, S Stone-Elander, G A Rogers, B Johansson, L Eriksson, S M Parsons, L Widén.   

Abstract

The regional cerebral distribution of [18F]NEFA, an aminobenzovesamicol (ABV), was studied in primates with PET. The binding was stereoselective and could be blocked but not displaced with vesamicol. The regional distribution pattern at late times, striatum > cortex > cerebellum, was corroborated by in vitro autoradiography using [3H]ABV and is consistent with known patterns of cholinergic innervation. Pretreatment with sigma 1 or D1 antagonists did not affect the striatal uptake, whereas D2 antagonists markedly augmented the uptake. This is consistent with the known induction of acetylcholine turnover in the striatum in response to D2-receptor blockade and demonstrates that the amount of [18F]-(-)-NEFA incorporated was influenced by the cholinergic activity in the target neurones.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8260611

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  7 in total

1.  Kinetics modeling and occupancy studies of a novel C-11 PET tracer for VAChT in nonhuman primates.

Authors:  Hongjun Jin; Xiang Zhang; Xuyi Yue; Hui Liu; Junfeng Li; Hao Yang; Hubert Flores; Yi Su; Stanley M Parsons; Joel S Perlmutter; Zhude Tu
Journal:  Nucl Med Biol       Date:  2015-11-07       Impact factor: 2.408

2.  In vitro and in vivo characterization of two C-11-labeled pet tracers for vesicular acetylcholine transporter.

Authors:  Prashanth K Padakanti; Xiang Zhang; Hongjun Jin; Jinquan Cui; Ruike Wang; Junfeng Li; Hubert P Flores; Stanley M Parsons; Joel S Perlmutter; Zhude Tu
Journal:  Mol Imaging Biol       Date:  2014-12       Impact factor: 3.488

3.  The impact of dopamine D2-like agonist/antagonist on [18F]VAT PET measurement of VAChT in the brain of nonhuman primates.

Authors:  Hui Liu; Zonghua Luo; Jiwei Gu; Yi Su; Hubert Flores; Stanley M Parsons; Yun Zhou; Joel S Perlmutter; Zhude Tu
Journal:  Eur J Pharm Sci       Date:  2019-11-15       Impact factor: 4.384

4.  No Dopamine Agonist Modulation of Brain [18F]FEOBV Binding in Parkinson's Disease.

Authors:  Roger L Albin; Prabesh Kanel; Teus van Laar; Sygrid van der Zee; Stiven Roytman; Robert A Koeppe; Peter J H Scott; Nicolaas I Bohnen
Journal:  Mol Pharm       Date:  2022-03-15       Impact factor: 4.939

5.  Multiple protonation states of vesicular acetylcholine transporter detected by binding of [3H]vesamicol.

Authors:  Parul Khare; Aubrey R White; Stanley M Parsons
Journal:  Biochemistry       Date:  2009-09-29       Impact factor: 3.162

6.  Effect of Dopamine D2 Receptor Antagonists on [18F]-FEOBV Binding.

Authors:  Anna Schildt; Erik F J de Vries; Antoon T M Willemsen; Bruno Lima Giacobbo; Rodrigo Moraga-Amaro; Jürgen W A Sijbesma; Aren van Waarde; Vesna Sossi; Rudi A J O Dierckx; Janine Doorduin
Journal:  Mol Pharm       Date:  2020-02-17       Impact factor: 4.939

Review 7.  In Vivo and In Vitro Characteristics of Radiolabeled Vesamicol Analogs as the Vesicular Acetylcholine Transporter Imaging Agents.

Authors:  Kazuma Ogawa; Kazuhiro Shiba
Journal:  Contrast Media Mol Imaging       Date:  2018-06-13       Impact factor: 3.161

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.